Pharmaceuticals are the next Trump tariff battleground - what will they mean for the NHS?
Stay up to date with notifications from The Independent
Notifications can be managed in browser preferences.
The impact Trump’s tariffs could have on the NHS
- Pharmaceutical companies, including UK-based AstraZeneca and GSK, are awaiting the impact of impending US tariffs proposed by President Donald Trump.
- The tariffs, expected to be similar to the 25 per cent tariffs imposed on auto parts, aim to boost drug production within the United States.
- While UK drug prices and NHS supply are unlikely to be immediately affected, long-term impacts on availability and research and development are possible.
- GSK, with over 50 per cent of its sales in the US, is optimistic about adapting but has acknowledged the uncertainty surrounding the tariffs.
- Pharmaceutical company share prices have already declined in anticipation of the tariffs, creating uncertainty in the sector.